08.07.2020 11:28
PharmaBiome AG, a pioneer in next-generation microbiome therapies, has obtained CHF 1.75 million as part of a bridge funding round to advance preclinical lead product PB002. Current shareholders and new investors, including the newly elected members of the board, contributed to the round. Thomas Meier and Patrik Forrer are the new board members.